HEPA
Hepion Pharmaceuticals
HEPA
HEPA
Delisted
HEPA was delisted on the 12th of May, 2025.
38 hedge funds and large institutions have $14.6M invested in Hepion Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 15 increasing their positions, 2 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
38
Holders Change
+9
Holders Change %
+31.03%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
15
Reduced
2
Closed
9
Calls
$1.51M
Puts
$1.56M
Net Calls
-$51K
Net Calls Change
-$146K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.95M |
| 2 |
BlackRock
New York
|
+$961K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$710K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$577K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$564K |
Top Sellers
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.02M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$512K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$329K |
| 4 |
Renaissance Technologies
New York
|
-$314K |
| 5 |
Squarepoint
New York
|
-$245K |
